---
title: "ZVSA.US (ZVSA.US) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/ZVSA.US/news.md"
symbol: "ZVSA.US"
name: "ZVSA.US"
parent: "https://longbridge.com/zh-HK/quote/ZVSA.US.md"
datetime: "2026-03-15T02:12:09.091Z"
locales:
  - [en](https://longbridge.com/en/quote/ZVSA.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ZVSA.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ZVSA.US/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/ZVSA.US/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/ZVSA.US/news.md)


# ZVSA.US (ZVSA.US) — 相關新聞

### [ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results](https://longbridge.com/zh-HK/news/266624288.md)
*2025-11-19T22:03:59.000Z*
> WESTON, Fla., Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- ZyVersa Therapeutics, Inc. ( OTCQB: ZVSA, or "ZyVersa" ) , a clinical-

### [ZyVersa Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0](https://longbridge.com/zh-HK/news/266619808.md)
*2025-11-19T21:27:36.000Z*
### [ZyVersa Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0](https://longbridge.com/zh-HK/news/266618807.md)
*2025-11-19T21:21:17.000Z*
### [Zyversa Therapeutics’ Promising Phase 2a Study on DKD Treatment](https://longbridge.com/zh-HK/news/262960513.md)
*2025-10-27T21:00:38.000Z*
> Zyversa Therapeutics is conducting a Phase 2a open-label study to evaluate the efficacy and safety of 2-Hydroxypropyl-β-